Aurobindo recalls mislabeled statin tablets from the U.S. market

drugs
A U.S. subsidiary of Aurobindo is pulling statins off the shelf after a mislabeling snafu. (Pixabay)

India-based Aurobindo has been repeatedly knocked by the FDA for its role in global “sartan” recalls for allowing tainted active pharmaceutical ingredients (APIs) into its drugs. Now, a mislabeling snafu is pulling even more of the drugmaker’s generics off U.S. shelves.

An American subsidiary of Aurobindo voluntarily recalled 2,352 bottles—each containing about 1,000 tablets—of generic statins after certain lots were found to have incorrect or missing labels and sometimes missing expiration dates, according to an FDA Enforcement Report.

Aurolife initiated the recall in late July after the product was distributed nationwide, the FDA said. Aurobindo, with 25 manufacturing plants globally, is one of the largest generic drug manufacturers in the world and the second-largest generics producer for the U.S.

The most recent recall is unrelated to Aurobindo pulling 80 lots of valsartan off U.S. shelves in February as part of a global FDA recall of “sartan” products linked to potentially carcinogenic APIs produced by Chinese and Indian manufacturers. The recalls from a variety of producers have resulted in shortages in the U.S. of losartan. 

RELATED: Aurobindo gets warning letter over valsartan recall mess

Suggested Articles

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.

An $8 billion jury verdict against Johnson & Johnson raised eyebrows back in October, but the judge has now slashed damages to just $6.8 million.